Tag Archives: NASDAQ:VTGN

A Director at VistaGen Therapeutics (NASDAQ: VTGN) is Buying Shares

Today, a Director at VistaGen Therapeutics (VTGN – Research Report), Jon Saxe, bought shares of VTGN for $25.16K. In addition to Jon Saxe, one other VTGN executive reported Buy trades in the last month. See today’s analyst top recommended stocks

The PRES. of VistaGen Therapeutics is Exercising Options

Today it was reported that the PRES. of VistaGen Therapeutics (VTGN – Research Report), Ralph Snodgrass, exercised options to buy 2,500 VTGN shares at $1.50 a share, for a total transaction value of $3,750. The options were close to expired

Maxim Group Sticks to Their Buy Rating for VistaGen Therapeutics (VTGN)

In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report), with a price target of $6. The company’s shares closed yesterday at $1.10. Palomeque noted: “FDA approved Janssen’s (Johnson

A Director at VistaGen Therapeutics is Exercising Options

Today it was reported that a Director at VistaGen Therapeutics (VTGN – Research Report), Jon Saxe, exercised options to buy 1,375 VTGN shares at $1.50 a share, for a total transaction value of $2,062. The options were close to expired

Maxim Group Keeps Their Buy Rating on VistaGen Therapeutics (VTGN)

Maxim Group analyst Caroline Palomeque maintained a Buy rating on VistaGen Therapeutics (NASDAQ: VTGN) today and set a price target of $6. The company’s shares opened today at $2. Palomeque said: “VistaGen announced that it has expanded its partnership with

VistaGen Therapeutics (VTGN) Received its Third Buy in a Row

After Maxim Group and Oppenheimer gave VistaGen Therapeutics (NASDAQ: VTGN) a Buy rating last month, the company received another Buy, this time from Chardan Capital. Analyst Gbola Amusa reiterated a Buy rating on VistaGen Therapeutics today and set a price